On August 10, 2018 the US Food and Drug Administration (FDA) approved ONPATTRO™, a nanomedicine for treating the devastating and usually lethal hereditary illness known as hereditary transthyretin-induced amyloidosis (hATTR). The approval of ONPATTRO™ has opened the door to a new era of gene therapies to treat most human diseases—including… Read More »“A new era of medicine:” NMIN thought leaders in Nature Nanotechnology
On August 21, 2019, the Board of Directors approved NMIN’s initial investments of $4.3M in nanomedicines research. Over a two-year period, NMIN will support 20 innovative projects led by Canadian leaders in nanomedicine drug delivery, gene therapy and diagnostics. These projects, hosted at six research centres across Canada, span a… Read More »NMIN releases first round of Research Investment
Over 100 delegates—researchers, trainees, partner organization representatives and other stakeholders—gathered at the Sheraton Vancouver Wall Centre in Vancouver, British Columbia, on September 13-14, 2019, to take part in NMIN’s first Scientific Meeting. Previous Next Read about the event in NMIN’s November 2019 Newsletter. See the Event Program for the full agenda, speakers’… Read More »NMIN holds its first Scientific Meeting
UBC attracts over $40M to host Networks of Centres of Excellence in nanomedicines Apr 16, 2019 – The NanoMedicines Innovation Network (NMIN) has been awarded $18.5 million in new funding from the Networks of Centres of Excellence (NCE), a federal program that connects teams of scientists across Canada to collaborate… Read More »NMIN receives funding from NCE Program